Mode
Text Size
Log in / Sign up

Review of 16 cases shows 25% mortality for pulmonary mucormycosis in DKA patients treated with amphotericin BTreatment for rare lung infection kills one in four patients with diabetic ketoacidosis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider early diagnosis and amphotericin B therapy for pulmonary mucormycosis in DKA patients.

This publication is a case report and literature review focusing on patients with diabetic ketoacidosis (DKA) complicated by invasive pulmonary mucormycosis caused by Rhizopus. The scope includes 16 patients, comprising one case report and 15 cases drawn from the literature. The setting of care was not reported for this aggregated group. The primary outcome assessed was overall mortality.

The authors report an overall mortality rate of 25%, which corresponds to 4 deaths among the 16 patients included in the analysis. No p-values or confidence intervals were reported for this finding. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the source material.

The intervention involved amphotericin B-based therapy and surgical resection for localized lesions. The authors note that the comparator was not reported. Key practice arguments include maintaining a high index of clinical suspicion in high-risk hosts, ensuring early pathological or molecular diagnosis, initiating prompt antifungal therapy alongside metabolic correction, and seeking timely surgical evaluation for localized lesions. Funding or conflicts of interest were not reported.

Diabetic ketoacidosis is a dangerous complication of diabetes where the body produces too much acid. When this condition leads to a rare lung infection called pulmonary mucormycosis, the outlook is often grim. A recent look at 16 patients shows that one in four people with this specific combination died. This group included one detailed case report and 15 cases gathered from medical literature. The infection was caused by a fungus known as Rhizopus. Doctors treated these patients with amphotericin B-based therapy and performed surgery to remove localized lesions when possible. They also worked to correct the underlying metabolic issues. The review did not report any specific safety signals or side effects for the drugs used in these cases. However, the data comes from a small number of patients and a mix of treatment settings. This means the results reflect real-world complexity rather than a single controlled experiment. The main lesson is clear: doctors must keep a high index of clinical suspicion in high-risk hosts. Early pathological or molecular diagnosis is vital. Prompt antifungal therapy alongside metabolic correction saves lives. Timely surgical evaluation for localized lesions remains a critical part of care. Maintaining these practices could improve outcomes for patients facing this deadly threat.

What this means for you:
Early diagnosis and surgery are vital for treating this rare lung infection in patients with diabetic ketoacidosis.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
ObjectiveTo investigate the rapid progression and key treatment strategies for invasive pulmonary mucormycosis caused by Rhizopus in patients with diabetic ketoacidosis (DKA).MethodsWe report a fatal case of severe Rhizopus pneumonia in a patient with DKA and conducted a systematic review of relevant cases from PubMed and Web of Science for descriptive analysis.ResultsA 39-year-old male with DKA developed severe lung lesions within days post-admission. Despite confirmation via pathological diagnosis and the initiation of liposomal amphotericin B therapy, the patient succumbed rapidly. Incorporating 15 cases identified from the literature, the total cohort comprised 16 patients, yielding an overall mortality rate of 25% (4/16). Cases involving DKA frequently exhibited narrow diagnostic windows and rapid progression to respiratory failure. Most cases (11/15) received amphotericin B-based therapy, and some with localized lesions (7/15) underwent surgical resection.ConclusionPulmonary mucormycosis with DKA can progress rapidly and carries high risk. Treatment typically involves amphotericin B preparations, supplemented by surgery for focal disease. Key strategies include maintaining a high index of clinical suspicion in high-risk hosts, early pathological/molecular diagnosis, prompt antifungal therapy alongside metabolic correction, and timely surgical evaluation for localized lesions.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.